



## OPEN ACCESS

## EDITED AND REVIEWED BY

Edgar Jaimes,  
Memorial Sloan Kettering Cancer Center,  
United States

## \*CORRESPONDENCE

Ming-Sheng Zhou,  
✉ zhousms1963@163.com  
Junjia Gao,  
✉ 48026486@qq.com

<sup>†</sup>These authors have contributed equally to  
this work

RECEIVED 01 November 2025

ACCEPTED 04 November 2025

PUBLISHED 12 November 2025

## CITATION

Liu Y, Fu R, Tang Q, Zhang Y, Cai R, Liu L, Jia H,  
Gao J and Zhou M-S (2025) Correction:  
Renoprotective effects of GHRH agonist  
MR409 is associated with reduced oxidative  
stress and ferroptosis in diabetic mice.  
*Front. Pharmacol.* 16:1737333.  
doi: 10.3389/fphar.2025.1737333

## COPYRIGHT

© 2025 Liu, Fu, Tang, Zhang, Cai, Liu, Jia, Gao  
and Zhou. This is an open-access article  
distributed under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#). The use,  
distribution or reproduction in other forums is  
permitted, provided the original author(s) and  
the copyright owner(s) are credited and that the  
original publication in this journal is cited, in  
accordance with accepted academic practice.  
No use, distribution or reproduction is  
permitted which does not comply with these  
terms.

# Correction: Renoprotective effects of GHRH agonist MR409 is associated with reduced oxidative stress and ferroptosis in diabetic mice

Yueyang Liu<sup>1†</sup>, Rong Fu<sup>1†</sup>, Qi Tang<sup>1</sup>, Yaoxia Zhang<sup>1</sup>, Ruiping Cai<sup>2</sup>,  
Limin Liu<sup>3</sup>, Hui Jia<sup>4</sup>, Junjia Gao<sup>3\*</sup> and Ming-Sheng Zhou<sup>1\*</sup>

<sup>1</sup>Shenyang Key Laboratory of Vascular Biology, Science and Experimental Research Center of Shenyang Medical College, Shenyang, China, <sup>2</sup>Department of Physiology, Shenyang Medical College, Shenyang, China, <sup>3</sup>Department of Cardiology, 2nd Affiliated Hospital Shenyang Medical College, Shenyang, China, <sup>4</sup>School of Traditional Chinese Medicine, Shenyang Medical College, Shenyang, China

## KEYWORDS

growth hormone-release hormone analogue, diabetic nephropathy, oxidative stress, ferroptosis, Klotho

## A Correction on

Renoprotective effects of GHRH agonist MR409 is associated with reduced oxidative stress and ferroptosis in diabetic mice

by Liu Y, Fu R, Tang Q, Zhang Y, Cai R, Liu L, Jia H, Gao J and Zhou M-S (2025). *Front. Pharmacol.* 16:1617185. doi: 10.3389/fphar.2025.1617185

There was a mistake in [Figure 3G](#) as published. The images for the MR409-treated group and the control group were inadvertently duplicated due to a file handling mistake during figure preparation. This was an unintentional error and does not reflect the actual experimental results, which were correctly recorded and remain valid. The corrected [Figure 3](#) appears below.

The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 3

MR409 attenuates the renal fibrosis in db/db and STZ-induced diabetic mice. Representative images of renal sections from db/db mice by Masson staining (A) and Sirius red staining (C), and correspondence semiquantitative analysis of positive staining area (B,D). Representative images of renal sections from STZ mice by Masson staining and Sirius red staining (E,G), and correspondence semiquantitative analysis of positive staining area (F,H). Protein expressions of TGFβ1 and Fibronectin in the kidney of db/db mice (I,J). Data are expression as mean  $\pm$  SEM. \*\*\* $P$  < 0.001, \*\* $P$  < 0.01, \* $P$  < 0.05 vs. control (Ctr) group; ### $P$  < 0.001, ## $P$  < 0.01, # $P$  < 0.05 vs. db/db group or STZ group.  $n$  = 6. Scale bar = 75  $\mu$ m in panels (A,C,G), Scale bar = 100  $\mu$ m in panels (E).